Manila Times Business
Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)
Lilly licenses Hanmi's sonefpeglutide (LAPSGLP-2 analog) for multiple indications SEOUL, South Korea, June 1, 2026 /PRNewswire/ -- Hanmi Pharm. Co., Ltd. ("Hanmi") today announced that they have entered into a license agreement for the development, manufacturing and commercialization of Hanmi's biologic drug candidate sonefpeglutide (LAPSGLP-2 analog) with Eli Lilly and Company ("Lilly"). Sonefpeglutide is a novel drug candidate incorporating Hanmi's proprietary long-acting platform technology,
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
NVIDIA Vera BlueField-4 STX Brings Agentic AI Storage Processing With In-Silicon Security
1h ago
NVIDIA Vera Rubin Ramps Into Full Production to Power Agentic AI Factories Worldwide
1h ago
NVIDIA DSX Gives Infrastructure Builders the Playbook for AI Factories
1h ago
Embracing a Zero-Carbon Future | The 6th LiuGong Global Customer Day Held in Liuzhou
1h ago